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Abstract: Oncobiotic transformation of the gut microbiome may contribute to the risk of breast cancer.
Recent studies have provided evidence that the microbiome secretes cytostatic metabolites that inhibit
the proliferation, movement, and metastasis formation of cancer cells. In this study, we show that
indolepropionic acid (IPA), a bacterial tryptophan metabolite, has cytostatic properties. IPA selectively
targeted breast cancer cells, but it had no effects on non-transformed, primary fibroblasts. In cell-based
and animal experiments, we showed that IPA supplementation reduced the proportions of cancer
stem cells and the proliferation, movement, and metastasis formation of cancer cells. These were
achieved through inhibiting epithelial-to-mesenchymal transition, inducing oxidative and nitrosative
stress, and boosting antitumor immune response. Increased oxidative/nitrosative stress was due to
the IPA-mediated downregulation of nuclear factor erythroid 2-related factor 2 (NRF2), upregulation
of inducible nitric oxide synthase (iNOS), and enhanced mitochondrial reactive species production.
Increased oxidative/nitrosative stress led to cytostasis and reductions in cancer cell stem-ness. IPA
exerted its effects through aryl hydrocarbon receptor (AHR) and pregnane X receptor (PXR) receptors.
A higher expression of PXR and AHR supported better survival in human breast cancer patients,
highlighting the importance of IPA-elicited pathways in cytostasis in breast cancer. Furthermore,
AHR activation and PXR expression related inversely to cancer cell proliferation level and to the
stage and grade of the tumor. The fecal microbiome’s capacity for IPA biosynthesis was suppressed
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in women newly diagnosed with breast cancer, especially with stage 0. Bacterial indole biosynthesis
showed correlation with lymphocyte infiltration to tumors in humans. Taken together, we found that
IPA is a cytostatic bacterial metabolite, the production of which is suppressed in human breast cancer.
Bacterial metabolites, among them, IPA, have a pivotal role in regulating the progression but not the
initiation of the disease.
Keywords: breast cancer; microbiome; oncobiome; indolepropionic acid; AHR; PXR; metastasis;
oxidative stress; nitrosative stress; epithelial-to-mesenchymal transition
1. Introduction
Dysbiotic microbiota, associated with oncological diseases, is termed the oncobiome. Oncobiosis
of the distal gut is associated with breast cancer [1–11]; importantly, among the oncobiome studies,
common microbiome changes were identified [12,13], suggesting a common root for the pathogenic
role of the oncobiome. It remained a question of whether oncobiotic transformation of the microbiome
has a causative role in carcinogenesis in breast cancer or if it is an epiphenomenon. Perturbing the
microbiota by antibiotic treatment exacerbated breast cancer in an animal model [14], and there is
suggestive supportive evidence in human population studies [15–22]. In good agreement with that,
probiotic treatment may be protective against the incidence of breast cancer [23–26]. Taken together,
the oncobiome could have a causative role in carcinogenesis.
While there have been several studies of potential oncobiosis in breast cancer, much less is
known about how oncobiosis affects breast cancer cells and the pathways by which it may contribute
to carcinogenesis. The oncobiome changes the behavior of breast cancer cells at multiple points.
Change from eubiosis to oncobiosis induces epithelial-to-mesenchymal transition (EMT) [27–29];
promotes migration and invasion [28]; reduces oxidative stress [30]; induces widespread metabolic
alterations [27,28] in cancers cells; alters the differentiation of cancer stem cells [28]; and suppresses
antitumor immunity [27,31]. These oncogenic processes support tumor growth [27,28], tumor
infiltration to the surrounding tissues [27,28], and metastasis formation [27,28,31,32]. Moreover, the
oncobiome has enhanced capacity to increase systemic estrogen levels by increasing enterohepatic
circulation [1,2,5]. The parent estrogens, estrone and estradiol, increase cell proliferation, and their
catechol–quinone metabolites cause oxidative DNA damage and mutagenesis [33]. The microbiome
also can interfere with the chemoradiotherapy and immunotherapy of breast cancer [34–36].
The actual molecular mechanisms through which the microbiome and cancer cells interact are
yet not characterized in detail. Nevertheless, there are two major routes identified to date. The
physical presence of the bacteria and their physical interaction with immune cells fine-tune the immune
system that directly impacts on the efficacy of immune therapies and antitumor immunity [20,35,37,38].
Additionally, bacterial metabolites can provide a link between the microbiome and cancer cells through
the circulation [34]. Among these metabolites, short-chain fatty acids, lithocholic acid, and cadaverine
have cytostatic properties [27,28,34,39]. In breast cancer, the metabolic capacity of the microbiome is
suppressed [4,27], suggesting that the production of cytostatic metabolites decrease in breast cancer.
Indolepropionic acid (IPA) is a bacterial metabolite that is produced by the deamination of
tryptophan [28,40]. The enzyme responsible for the formation of indolepropionic acid is tryptophanase
(TnaA) [40]. Approximately, 4–6% of tryptophan is metabolized to indole derivatives through bacterial
enzymes [41]. In germ-free mice, serum tryptophan levels increase, highlighting the burden of microbial
degradation on tryptophan levels [42–46]. It is of note that besides the indicated indole derivatives, the
microbiome is capable of synthesizing a large set of other indole-derivative metabolites [46,47]. In the
pathway that yields IPA, tryptophan is converted to indole lactate, then to indole acrylic acid, and
subsequently to IPA [48]. In this study, we assessed the cytostatic properties of a bacterial metabolite,
IPA, as well as changes to its production in women with breast cancer.
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2. Materials and Methods
All methods were performed according to the relevant guidelines.
2.1. Chemicals
Chemicals, among them, indolepropionic acid (IPA), glutathione (GSH), N-acetyl-cysteine (NAC),
Mito-TEMPO, and ketoconazole were from Sigma-Aldrich (St. Louis, MO, USA) unless otherwise
stated. IPA was used, 0.4 µM and 0.8 µM, which corresponds to the normal human serum concentration
of IPA [40,49,50]. GSH and NAC antioxidants were used at a final concentration of 5 mM. The
mitochondria-targeted antioxidant Mito-TEMPO was used at a concentration of 5 µM. The aryl
hydrocarbon receptor (AHR) inhibitor, CH223191, was obtained from MedChemExpress (MCE,
Monmouth Junction, NJ, USA) and was applied at a concentration of 10 µM. Pregnane X receptor (PXR)
downstream signaling was inhibited using ketoconazole at a final concentration of 25 µM [51,52]. The
Silencer Select siRNAs targeting AHR (AHR—siRNA ID: s1198) and PXR (NR1I2—siRNA ID: s16910)
and the negative control siRNA #1 (cat.no. 4390843) were obtained from Thermo Fisher Scientific
(Waltham, MA, USA) and each was used at a final concentration of 30 nM.
2.2. Cell Culture
4T1murine breast cancer cells were maintained inRPMI-1640 (Sigma-Aldrich, R5886) medium containing
10% FBS, 1% penicillin/streptomycin, 2 mM L-glutamine, and 1% pyruvate at 37 ◦C with 5% CO2.
SKBR-3 human breast cancer cells were maintained in DMEM (Sigma-Aldrich, 1000 mg/L glucose,
D5546) medium containing 10% FBS, 1% penicillin/streptomycin, 2 mM L-glutamine at 37 ◦C with 5% CO2.
Human primary fibroblasts cells were maintained in DMEM (Sigma-Aldrich, 1000 mg/L glucose,
D5546) medium containing 20% FBS, 1% penicillin/streptomycin, 2 mM L-glutamine at 37 ◦C with 5% CO2.
2.3. In Vitro Cell Proliferation Assays
Cellular proliferation was assessed using sulforhodamine B (SRB) assay and colony-forming assay
as described in [53]. Cells were seeded in 96-well plates (4T1—1500 cells/well; MDA-MB-231—3000
cells/well; SKBR-3—5000 cells/well; MCF7—4000 cells/well; human fibroblast—7500 cells/well) and were
treated with the indicated concentrations of IPA or Mito-TEMPO mitochondria-targeted antioxidant
(5 µM) at the presence of IPA (0.8 µM) for 24 h. Then, cells were fixed in 50% trichloroacetic acid
(TCA—final concentration: 10%), and the plates were incubated for 1 h at 4 ◦C. Plates were washed 5
times with water and stained with 0.4% (w/v) sulforhodamine B solution in 1% acetic acid. Unbound
dye was removed by washing 5 times with 1% acetic acid. A bound stain was solubilized with 10
mM Tris base, and the absorbance was measured on an automated plate reader (Thermo Labsystems
Multiskan MS, Walthman, MA, USA) at 540 nm.
For colony-forming assays, cells were seeded in a 6-well plate (4T1—500 cells/well; MCF7—1000
cells/well; SKBR-3—1500 cells/well) in complete medium and were cultured with the indicated
concentrations of IPA for 7 days. After treatment, the plates were washed twice with PBS. Colonies
were fixed in methanol for 15 min, dried, and stained with May–Grünwald–Giemsa solution for 20
min. Cells were washed with water, and the colonies were determined using Image J software (Image
J2 version) [54].
2.4. Detection of Cell Death
IPA-induced cytotoxicity was assessed by propidium iodide (PI; Biotium, Fremont, CA, 40016, USA)
uptake assays as in [55]. Cells were seeded in a 6-well plate (4T1—75,000 cells/well; MCF7—150,000
cells/well; SKBR-3—200,000 cells/well; human fibroblast—200,000 cells/well) and treated with the indicated
concentrations of IPA for 24 h; then, they were stained with 100 µg/mL PI for 30 min at 37 ◦C, washed once
in PBS, and analyzed by flow cytometry (FACS Calibur, BD Biosciences).
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To assess changes in apoptotic and necrotic cell death, we used an Annexin V+PI double staining
assay kit (Invitrogen, OR, USA, V13242). Cells were seeded in 6-well plates (4T1—75,000 cells/well;
MCF7—150,000 cells/well; SKBR-3—200,000 cells/well; human fibroblast—200,000 cells/well) treated with
the indicated IPA concentrations for 24 h. Then, cells were stained with 100 µg/mL PI solution and 5 µL
FITC Annexin V according to the manufacturer’s instructions. The number of apoptotic and necrotic cells
were counted using a FacsCalibur flow cytometer (Beckton-Dickinson Franklin Lakes, NJ, USA).
2.5. Electric Cell–Substrate Impedance Sensing (ECIS)
ECIS (Electric cell–substrate impedance sensing) measurements (ECIS model Zθ, Applied BioPhysics
Inc., Troy, NY, USA) were used to monitor cell-to-cell and cell-to-surface connections. 4T1 cells were seeded
(40,000 cells/well) on type 8W10E arrays. After 20 h, cells were treated with vehicle, 0.4 µM, or 0.8 µM IPA,
and total impedance values were measured for 24 h. Multifrequency measurements were taken at 62.5, 125,
250, 500, 1000, 2000, 4000, 8000, 16,000, 32,000 and 64,000 Hz. The reference well was set to a no-cell control
with complete medium. ECIS assays were performed similarly to [27].
2.6. Immunocytochemisry
Immunocytochemistry was performed similarly to [27]. 4T1 cells were grown on glass coverslips
for 1 day and treated with the indicated concentrations of IPA for 24 h. Then, the cells were washed in
PBS and fixed with 4% paraformaldehyde for 15 min and permeabilized using 1% Triton X-100 in PBS
for 5 min. Then, cells were blocked with 1% bovine serum albumin (BSA) in PBS for 1 h and incubated
with TexasRed-X Phalloidin (T7471, 1:150, Thermore Fisher, Waltham, MA, USA) for 1 h at 4 ◦C. Cells
nuclei were visualized with DAPI (R37606, 1:10, Thermo Fischer Scientific Inc., Rockford, IL, USA) and
rinsed in phosphate buffered saline (PBS) twice for 10 min. Coverslips mounted in Mowiol/Dabco solution.
Confocal images were acquired with a Leica TCS SP8 confocal microscope and were processed using LAS
AFv3.1.3 software. Typical mesenchymal-like and epithelial-like morphology of 4T1 cells are shown in [27].
2.7. mRNA Preparation and Quantitation
Reverse transcription-coupled PCR (RT-qPCR) was performed similarly to [56]. Total RNA from cells
were isolated using TRIzol reagent according to the manufacturer’s instructions (Invitrogen Corporation,
Carlsbad, CA, USA). For the assessment of the expression of indicated genes, 2 µg of RNA was reverse
transcribed using a High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City,
CA, USA). The qPCR reactions were performed with the qPCRBIO syGreen Lo-ROX Supermix (PCR
Biosystems Ltd., London, UK) on a Light-Cycler 480 Detection System (Roche Applied Science, Basel,
Switzerland). Gene expression was normalized to the geometric mean of human 36B4 and cyclophyllin
values. Primers are listed in Table 1.
Table 1. Murine and human primers used in reverse transcription-coupled PCR (RT-qPCR) reactions.
Gene Symbol Murine Forward Primer (5′–3′) Murine Reverse Primer (5′–3′)
CAT CCTTCAAGTTGGTTAATGCAGA CAAGTTTTTGATGCCCTGGT
VIM CTCCAGAGAGAGGAAGCCGAAAG CCTGGATCTCTTCATCGTGCAGT
FgfBp1 CAAGGTCCAAGAAGCTGTCTCCA AGCTCCAAGATTCCCCACAGAAC
Cyclophilin A TGGAGAGCACCAAGACAGACA TGCCGGAGTCGACAATGAT
36B4 AGATTCGGGATATGCTGTTGG AAAGCCTGGAAGAAGGAGGTC
Gene Symbol Human Forward Primer (5′–3′) Human Reverse Primer (5′–3′)
AHR TTGAACCATCCCCATACCCCAC GAGGTTCTGGCTGGCACTGATA
PXR AGTGAAGGTTCCCGAGGACATG TTGTCACAGAGCATACCCAGCA
Cyclophilin A GTCTCCTTTGAGCTGTTTGCAGAC CTTGCCACCAGTGCCATTATG
36B4 CCATTGAAATCCTGAGTGATGTG GTCGAACACCTGCTGGATGAC
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2.8. Bacterial TnaA DNA Quantitation
The human fecal DNA library from breast cancer patients and matched control women was
published in [3]. For the assessment of the abundance of bacterial tryptophanase (TnaA) coding DNA
in human fecal, DNA samples consisting of 10 ng of DNA were used for qPCR reactions. Primers are
listed in Table 2.
Table 2. Primers for the determination of abundance of tryptophanase (TnaA) using RT-qPCR reactions.
Gene Symbol Forward Primer (5′–3′) Reverse Primer (5′–3′)
Alistipes shahii GCCTCGAAGACGATCAAGGAGAT TCGAACATGATGCTGAACGACAT
Providencia rettegri CGTTTACGTGAGGGAGGGATTTC ACCGCACGAACACCAGATTCTAA
Bacteriodes xylanisolvens AACTGGAAATCCCGTTCAAAGGA GTACGGGTTTGCCGTATTTGTCA
Clostridium sp. GATGGAACGTCCAAACACTTTCG ATATTTTCCGCCTTCCGGAACTT
2.9. Quantitation of Fecal E. coli TnaA Protein
Fecal proteins were isolated as described in [28] and [57]. Fecal samples (100 mg) were lysed in
500 µL RIPA buffer (50 mM Tris, 150 mM NaCl, 0.1% SDS, 1% Triton X-100, 0.5% sodium deoxycholate,
1 mM EDTA, 1 mM Na3VO4, 1 mM phenylmethylsulfonyl fluoride (PMSF), 1 mM NaF, protease
inhibitor cocktail), and sonicated (Qsonica Q125 Sonicator, Newtown, Connecticut) 3 times for 30 s
with 50% amplitude. After centrifugation, 8 µL β-mercaptoethanol and 25 µL 5 X SDS sample buffer
(50% glycerol, 10% SDS, 310 mM Tris HCl, pH 6.8, 100 mM dithiotreitol (DTT), 0.01% bromophenol
blue) were added to each 100 µL extract. Then, fecal protein samples were heated for 10 min at 96 ◦C
and held on ice until loading. Protein extract (40 µL) was loaded on 8% SDS-PAGE gels, and proteins
were separated and transferred onto nitrocellulose membrane. Ponceau-red staining took place after
transfer, but before blocking. Ponceau-stained membranes were photographed and used in subsequent
analyses. Membranes were cut at the 70 kDa standard, and the top part was blotted for TnaA (E. coli
TnaA, 1:2000, Assaypro (33517–05111)). Membranes were blocked in Tris buffered saline-Tween 20
(TBST) containing 5% BSA for 1 h and incubated with anti-LdcC primary antibody overnight at 4 ◦C.
After washing with 1 x TBS-TWEEN solution, the membranes were probed with peroxidase-conjugated
IgG antibodies (1:2000, Cell Signaling Technology, Inc., Beverly, MA, USA). Bands were visualized
by enhanced chemiluminescence reaction (SuperSignal West Pico Solutions, Thermo Fisher Scientific
Inc., Rockford, IL, USA). Blots were evaluated by densitometry using Image J software, and antibody
signals were normalized to total protein stained by Ponceau-red (Sigma-Aldrich).
2.10. Aldefluor Assay
Aldehyde dehydrogenase (ALDH) activity was measured using an Aldefluor Stem Cell kit
(StemCell Technologies, Vancouver, BC, Canada). 4T1 cells were seeded on 6-well plates (4T1—100,000
cells/well) and treated with different concentrations of IPA for 24 h. Then, cells were collected and
prepared according to the manufacturer’s instructions. For positive control samples, the SKBR-3 cell
line was used based on the manufacturers’ instructions. Changes in the level of ALDH were determined
by flow cytometry, and the results were analyzed by using Flowing Software 2.5.1. Aldefluor assay for
assessing stemness was performed similarly to [28,58,59].
2.11. SDS-PAGE and Western Blotting
SDS PAGE and Western blotting was performed as in [60]. Cells were lysed in RIPA buffer (50 mM
Tris, 150 mM NaCl, 0.1% SDS, 1% TritonX 100, 0.5% sodium deoxycolate, 1 mM EDTA, 1 mM Na3VO4,
1 mM PSMF, 1 mM NaF, protease inhibitor cocktail). Protein extracts (20–50 µg) were separated on
10% SDS polyacrylamide gels and blotted onto nitrocellulose membranes. Then, membranes were
blocked in TBST containing 5% BSA for 1 h and incubated with primary antibodies overnight at 4
◦C. After washing with 1 × TBST solution, the membranes were probed with IgG HRP-conjugated
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peroxidase secondary antibodies (1:2000, Cell Signaling Technology, Inc., Beverly, MA, USA). Bands
were visualized by enhanced chemiluminescence reaction (SuperSignal West Pico Solutions, Thermo
Fisher Scientific Inc., Rockford, IL, USA). Blots were quantified by densitometry using the Image J
software. Densitometric analysis is represented as a separate supplementary file, and it is also uploaded
among the primary data. The primary and secondary antibodies are listed in Table 3.
Table 3. List of antibodies used for Western blot.
Antibody Dilution Vendor
4-HNE 1:1000 Abcam (ab46545)
Nitrotyrosine 1:1000 Millipore (06–284)
iNOS 1:1000 Novus (NB300–605)
NRF2 1:1000 Abcam (ab31163)
LC3 1:1000 Cell Signaling (#13082)
Phospho-AMPKα (Thr172) 1:1000 Cell Signaling (#2535)
AMPKα 1:1000 Cell Signaling (#5832)
Phospho-ACC (Ser79) 1:1000 Cell Signaling (#3661)
ACC 1:1000 Cell Signaling (#3676)
FOXO1 1:1000 Cell Signaling (#9454)
PGC1β 1:1000 Abcam (ab176328)
E-cadherin 1:1000 Cell signaling (#3195)
Vimentin 1:1000 Cell signaling (#5741)
Snail 1:1000 Cell signaling (#3879)
β-Catenin 1:1000 Sigma-Aldrich (C7082)
β-Actin 1:20000 Sigma-Aldrich (A3854)
E. coli TnaA 1:2000 Assaypro (33517–05111)
β-Actin 1:20000 Sigma-Aldrich (A3854)
Anti-rabbit IgG, HRP-linked antibody 1:2000 Cell Signaling (#7074)
Anti-Mouse IgG, Peroxidase antibody 1:2000 Sigma-Aldrich (A9044)
2.12. Determination of Lipid Peroxidation
Lipid peroxidation was evaluated by determining the production rate of thiobarbituric acid-reactive
substrate using the thiobarbituric acid-reactive substances (TBARS) assay as described in [61]. The
4T1 cells were seeded in T75 flasks and exposed to different concentrations of IPA or Mito-TEMPO
mitochondria-targeted antioxidant (5 µM)/GSH and NAC antioxidants (5 mM)/AHR (10 µM) and
PXR (25 µM) inhibitors together with IPA (0.4 µM or 0.8 µM) for 24 h. Cells were washed in PBS
and scraped; then, they were collected by centrifugation. After adding 8.1% SDS, 20% acetic acid,
0.8% thiobarbituric acid (TBA), and distilled water to the pellet, the samples were heated at 96 ◦C
for 1 h. Samples were cooled down on ice and centrifuged. The absorbance of the supernatants was
identified at 540 nm. The levels of 4-hydroxynonenal (4HNE)-modified proteins, as a marker for lipid
peroxidation were also assessed using Western blotting.
2.13. Animal Study
Animal experiments were approved by the Institutional Animal Care and Use Committee at the
University of Debrecen and the National Board for Animal Experimentation (1/2015/DEMÁB) and
were performed according to the NIH guidelines (Guide for the care and use of laboratory animals)
and applicable national laws. Animal studies are reported in compliance with the ARRIVE guidelines.
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Experimental animals were BALB/c female mice (14–16 weeks of age, 20–25 g). Animals were
randomized for all experiments. Mice were bred in the “specific pathogen-free” zone of the Animal
Facility at the University of Debrecen and kept in the “minimal disease” zone during the experiments.
No more than 5 mice were housed in each cage (standard block shape 365 × 207 × 140 mm, surface
530 cm2; 1284 L Eurostandard Type II. L from Techniplast). Cages were changed once a week on the
same day. Animals had paper tubes to enrich their environment. The dark/light cycle was 12 h, and
temperature was 22 ± 1 ◦C. Mice had ad libitum access to food and water (sterilized tap water). The
animal facility was overseen by a veterinarian. A total of 20 female mice were used in the study: 10
randomly selected control and 10 IPA-fed mice.
4T1 cells were suspended (2 × 106/mL) in ice-cold PBS-Matrigel (1:1, Sigma-Aldrich) at a 1:1 ratio.
Twenty female BALB/c mice received 50 µL injections to their second inguinal fat pads on both sides
(105 cells/injection site). Tumor growth and animal wellbeing was controlled daily.
IPA treatment was administered by oral gavage at the dose of 1 nmol/g (0.18921 mg/kg) body
weight once a day on each day of the experiment. The dose was planned not to exceed the serum
reference concentration of IPA [40,49,50]. Animals received single daily oral IPA treatment. IPA stock
was prepared in sterilized tap water at 100 × concentration (15 mM) for storage at −20 ◦C. IPA stock
was diluted each day to a working concentration of 150 µM in sterile tap water before treatment.
Animals received a daily oral dose of 100 µL/30 g bodyweight from the IPA solution (10 mice) or vehicle
(sterilized tap water, 10 mice). Researchers involved in IPA and vehicle solution administration were
blinded. Treatment was administered every day at the same time between 9:00 and 11:00. Animals
were sacrificed on day 14 post grafting by cervical dislocation; then, primary tumors and metastases
were collected for subsequent analysis.
Upon autopsy, primary tumors were visually evaluated and scored based on their infiltration rate
into surrounding tissues and the macroscopic appearance of the tumor [27,28]. Tumors were classified
as a “low infiltration” class if the primary tumor remained in the mammary fat pads without any
attachment to muscle. A “medium infiltration” tumor means that the tumor mass attached to the
muscle tissue, but it did not penetrate to the abdominal wall. In case the tumor grew into the muscle
tissue and totally penetrated the abdominal wall, it was scored as a “high infiltration” tumor. For
the assessment of primary tumor infiltration rate, the researchers were blinded. Both primary and
metastatic tumor masses were removed from the animals and were measured on analytical balance in
preweighed Eppendorf tubes. From the sections of HE-stained, formalin-fixed, paraffin-embedded
tumor tissues tumor-infiltrating lymphocyte (TIL) content was determined as the number of TILs per
100 tumor cells.
2.14. Human Studies
We assessed the abundance of the bacterial TnaA coding DNA in human fecal DNA samples. We
used three cohorts in the study.
2.14.1. Cohort 1
Cohort 1 consisted of fecal DNA samples and were used for the quantitation of the TnaA coding
DNA. The cohort involved 48 controls and 46 breast cancer patients.
The human feces samples were collected from healthy volunteers and breast cancer patients
by collaborators at the National Cancer Institute (NCI), Kaiser Permanente Colorado (KPCO), the
Institute for Genome Sciences at the University of Maryland School of Medicine, and RTI International.
The study protocol and all study materials were confirmed by the Institutional Review Boards at
KPCO, NCI, and RTI International (IRB number 11CN235). The study results were published in [3].
Informed consent was obtained from the study participants. That cohort was designed and powered
to compare healthy controls versus breast cancer patients, but we also stratified patients using the
available clinical data.
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2.14.2. Cohort 2
This cohort was used in assessing the intratumoral expression of IPA receptors. The tissue
microarray (TMA) study was carried out using archived tissue blocks of 88 breast cancer patients.
Formalin-fixed, paraffin-embedded tissues from breast cancer surgeries were collected, and tissue
microarray (TMA) blocks were built [62]. The cohort is described in [30]. The study was approved by
the local ethical committee at the University of Debrecen. That cohort was designed and powered
to compare healthy controls versus breast cancer patients, but we also stratified patients using the
available clinical data.
2.14.3. Cohort 3
Fecal protein expression was assessed in a cohort of female breast cancer patients of 35 participants
with a mean age of 57 years. Samples from stage I–III and Nottingham grade 1–3 patients were used in
the study. The average stage and grade were not statistically different amongst the groups. The cohort
was published in [57].
The collection and biobanking of feces were authorized by the Hungarian national authority
(ETT). Patients and healthy volunteers meeting the following criteria were excluded from the study:
(1) has a previous history of breast cancer or had been operated due to neoplasia, (2) has a disease
of unknown origin, (3) has a chronic contagious disease, (4) had contagious diarrhea 6 months prior
to enrollment, (5) taken antibiotics within the 6 months prior to enrollment, (6) had chemotherapy,
biological therapy, or immunosuppressive therapy 6 months prior to enrollment, (7) used intravenous
drugs 12 months prior to enrollment, (8) had piercing, tattooing, acupuncture, or other endangering
behavior or action 12 months prior to enrollment, (9) exposure to an allergen to which the enrolled
individual had been sensitized to, or (10) underwent colonoscopy 12 months prior to enrollment. The
first morning feces was sampled; samples were frozen and deposited in the biobank within two hours
after defecation. Samples were stored at −70 ◦C until subsequent use. We obtained informed consent
from study participants. The patient’s routine pathological data were assessed in the study and were
compared to the fecal expression of E. coli TnaA.
2.15. Tissue Microarray, Immunohistochemistry and Analysis
TMA in combination with immunohistochemistry was performed as in [62]. From every block,
there were three replicates, and the staining was assessed applying an H-score system [63]. In
immunohistochemical studies, Leica Bond MaxTM protocol was used. The antibodies and conditions
are listed in Table 4.
Table 4. List of antibodies and conditions used in tissue microarray (TMA) analysis. AHR: aryl
hydrocarbon receptor, PXR: pregnane X receptor.
Antibody Dilution Vendor
PXR 1:1000 Thermo Fisher Scientific (PA5–72551)
AHR 1:200 Sigma-Aldrich (HPA029722)
2.16. Database Screening
The kmplot.com database [64] was used to examine the connection between gene expression
levels (AHR and PXR) and breast cancer survival in humans. The case numbers are listed in Table 5.
The sequence of the TnaA ORFs was retrieved from the KEGG (www.genome.jp/kegg/), the
PATRIC (www.patricbrc.org/) and the Uniprot (www.uniprot.org) databases
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2.17. Statistical Analysis
For the comparison of two groups, we used the two-tailed Student’s t-test, unless stated otherwise.
Fold data were log2 transformed to achieve normal distribution. Statistical significance was determined
for multiple comparisons with one-way analysis of variance test (ANOVA) followed by Tukey’s or
Dunnett’s honest significance difference (HSD) post-hoc test. All data are presented as average ± SEM
unless stated otherwise. Texas Red-X Phalloidin-labeled fluorescent pictures were analyzed using
Cell Profiler 2.0 followed by Advanced Cell Classifier 3.0. FACS results were analyzed using Flowing
Software 2.0. Statistical analysis was done using GraphPad Prism 7 software unless stated otherwise.
3. Results
3.1. Indolepropionic Acid Reduces the Progression of Breast Cancer In Vivo
As a first step, we examined the effects of IPA supplementation on tumor growth by grafting
4T1 breast cancer cells to 20 female Balb/c mice to the left and right side (200,000 cells to each site).
Half of the mice received vehicle (sterilized tap water) as control, while the other half of the mice
received IPA (1 nmol/g bodyweight). Per os IPA treatment did not inhibit the growth of the primary
tumor, as neither the number of tumors, nor the total, nor the mass of primary tumors differed with
IPA treatment (Figure 1A–C). However, IPA treatment drastically reduced the level of infiltration to
the surrounding tissues (Figure 1D). IPA treatment reduced the number of mice bearing metastases
(Figure 1E) and the total mass of metastases (Figure 1F), although the mass of the individual metastases
did not change (Figure 1G). We assessed the histology of the primary tumors and found that the
infiltration of lymphocytes was increased and the mitosis score of the tumor cells was decreased in the
IPA-treated mice (Figure 1H).
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Figure 1. S pplementation of mice transpla ted with 4T1 breast c ncer cells with indolepro i nic a id
(IPA) reduces metastatic burden. Female Balb/c mice (n = 10/10, 3 months of age) were grafted with
4T1 cells and were treated with IPA (1 nmol/g q.d. p.o.) or vehicle (VEH) (n = 10/10) for 14 days; then,
the mice were terminated. Upon autopsy (A), the total number and (B) total and (C) individual mass
of primary tumors were determined. (D) The infiltration of the primary tumors to the surrounding
tissues was scored. The (E) number of mice with metastasis were plotted, and the (F) total, as well
as the (G) individual mass of the metastases were measured. In tissue sections of formalin-fixed,
paraffin-embedded tissue specimens from the primary tumors (H), lymphocyte infiltration and (I)
mitosis score were determined. Statistical significance was determined using Student’s t-test, except for
panels D, E, and I, where chi-squa tests ere conducted. *** in icate statistically significant difference
between vehicle and treated groups at p < 0.001.
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3.2. Indolepropionic Acid Inhibits Hallmarks of Cancer
IPA reduced the proliferation of 4T1 cells in colony-forming assays (Figure 2A).Cancers 2020, 12, x FOR PEER REVIEW 10 of 27 
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in the concentrations in icated for 24 h; the ratio of necrot c and apoptotic cells were determined with
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measured by flow cytometry (n = 3). (D) SKBR-3 (5000 cel s/ ell) were seeded in 96-well plates and
then re treated with IPA in th concentr tions indicated for 24 h; then, total protein content wa
assessed in sulforhodamine B (SRB) assays (n = 3). (E) SKBR-3 (200,000 cells/well) cells were seeded in
6-well plates and wer treat d with IPA in th concentrations indic ted for 24 h. The ratio of necrotic
and apoptotic cells were determined with staining by propidium–iodide; then, they w re analyzed by
flow cytometry. (F) SKBR-3 (200,000 cells/well) cells were seeded in 6-well plates and were treated with
IPA in the concentrations indicated for 24 h. The ratio of necrotic and apoptotic cells were determine
with staining by propidium–iodide–FITC Annexin double staining using the V/Dead Cell Apoptosis
Kit and measured by flow cytometry (n = 3). (G) Human fibroblast (7500 cells/well) cells were seeded
in 96-well plates and then were treated with IPA in the concentrations indicated for 24 h; then, the
total protein content was assessed in SRB assays (n = 3). (H) Human fibroblast (20,000 cells/well) cells
were seeded in 6-well plates and then were treated with IPA in the concentrations indicated for 24 h.
Then, the ratio of necrotic and apoptotic cells were determined with staining by propidium–iodide and
analyzed by flow cytometry (n = 3). Fold data were log2 transformed to achieve normal distribution.
Statistical significance was determined using ANOVA test followed by Tukey’s post-hoc test, except
for panels D, E, and F, where Dunnett’s post-hoc tests were conducted. * or *** indicate statistically
significant difference between control and treated samples at p < 0.05 or p < 0.001, respectively.
Other bacterial metabolites that possess cytostatic effects in breast cancer, such as lithocholic acid or
cadaverine are only cytostatic; they are not toxic [27,28]. Therefore, we assessed IPA in concentrations
corresponding to the reference concentration. In good agreement with the previously identified
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metabolites, IPA did not increase either the proportions of propidium–iodide positive necrotic or the
Annexin–FITC–propidium–iodide double-positive apoptotic cells (Figure 2B,C).
We also assessed whether the effects, described above, are specific for only 4T1 cells, but they can
also be elicited in another breast cancer cell line. IPA, in a similar concentration range used for 4T1
cells, decreased cell proliferation as measured in SRB assays; it did not increase necrotic or apoptotic
cell death in SKBR-3 (Figure 2D–F).
Finally, we found that IPA does not inhibit cell proliferation or exert cytotoxicity in primary,
non-transformed human fibroblasts (Figure 2G,H), similarly to other cytostatic metabolites [27,28,65].
Next, we assessed whether IPA can modulate other cancer hallmarks that were regulated by other
bacterial metabolites [34]. Although the role of oxidative stress in breast cancer was long debated,
recent studies consistently showed that increased oxidative stress is responsible for cytostasis or cancer
cell death [30,66–70]. We assessed different oxidative stress markers to explore the redox status of
IPA-treated cancer cells. IPA treatment increased lipid peroxidation, as measured by TBARS assay and
by the formation of 4HNE (Figure 3A,B), which is indicative of enhanced oxidative stress. Enhanced
oxidative stress was in parallel with the reduction in the expression of nuclear factor erythroid 2-related
factor 2 (NRF2), which is a transcription factor responsible for the expression of antioxidant enzymes,
such as catalase. In parallel, we observed the enhanced expression of inducible nitric oxide synthase
(iNOS), an enzyme promoting nitrosative stress (Figure 3C,D).
Finally, we assessed markers of cellular energy stress (pACC, ACC, FOXO1, and PGC1β) and
cancer stem cell-ness (aldehyde dehydrogenase [71]). IPA treatment reduced the proportions of cancer
stem cells (Figure 3F), while inducing the markers of cellular energy stress (Figure 3E).
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Figure 3. Indol propi nic acid (IPA) induced oxidative stress, llular energy stress, and decreased the
proportions of cancer stem cells. 500,000 cells/well 4T1 cells were treated with IPA in the concentrations
indicated for 24 h; then, (A) lipid peroxidation was measured by TBARS assay, and (B) 4HNE expression
was assessed by Western blotting (representative figure, n = 3). In the same cells (C), the protein
expression of NRF2 (at 68 kDa) and NOS were de ermin d by Western blotti g (n = 3), while (D)
the mRNA expression of catalase (cat) was determined by RT-qPCR (n = 3). (E) The expression of
the indicated proteins (pACC, ACC, FOXO1, and PGC-1β) were determined by Western blotting (n
= 3, except for PGC-1β, where n = 2). (F) 100,000 cells/well 4T1 cells were treated with the indicated
concentration of IPA for 24 h; then, the prop rtions f al ehyd dehydrogenase-positive cells were
determined in Aldefluor assays using flow cytometry (n = 3). For Western blots, a typical experiment
was displayed. Fold data were log2 transformed to achieve normal distribution. Statistical significance
was determined using the ANOVA test followed by Dunnett’s post-hoc test, except for panel F, where
Student’s t-test was used. * and *** indicate statistically significant difference between control and
treated samples at p < 0.05 and p < 0.001, respectively.
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Another important feature of breast cancer is epithelial-to-mesenchymal transition (EMT). The
IPA treatment of 4T1 cells reverted EMT that was evidenced by the dose-dependent conversion of 4T1
cells to epithelial morphology (Figure 4A).
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In good agreement with that, IPA treatment induced the resistance of a cellular monolayer to
the electric current, indicative of better cell-to-cell and cell-to-surface binding (Figure 4B). Finally,
we assessed epithelial and mesenchymal markers at the protein and mRNA level. IPA treatment
induced the expression of mesenchymal makers (Vimentin (Vim), fibroblast growth factor-binding
protein1 (FgfBp1), snail family transcriptional repressor-1 (Snail), and β-catenin; and it upregulated
the expression of E-cadherin, which is an epithelial marker (Figure 4C,D).
3.3. IPA-Induced Cytostatic and Antineoplastic Effects Are Mediated by Reactive Species Production
EMT, as well as cancer stem cell characteristics are modulated by reactive species [72,73]. With
enhanced oxidative stress upon IPA treatment, it was likely that the suppression of these features
may be oxidative stress-driven. To get an insight on whether IPA can modify oxidative stress to
exert cytostatic effects on breast cancer cells, we assessed the effects of thiol reductants glutathione
(GSH) and n-acetyl-cysteine (NAC), as well as mitochondria-targeted antioxidant Mito-TEMPO, on
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IPA-mediated cancer hallmarks. As expected, the application of general thiol reductants (reduced
glutathione (GSH) and N-acetyl-cysteine (NAC)) reduced the IPA-induced increase in thiobarbituric
acid-reactive substances (Figure 5A), suggesting a reduction in IPA-induced oxidative stress.
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Figure 5. Indolepropionic acid (IPA)-elicited oxidative stress has central role in mediating
IPA-elicited antineoplastic effects. 4T1 cells (500,000 cells/well, TBARS; 100,000 cells/well, ALDH; 1500
cells/well, SRB) were treated with IPA in the concentrations indicated for 24 h with or without the
antioxidants, as indicated. Subsequently, (A) thiobarbituric acid-reactive substances, (B) the fraction of
Aldefluor-positive cells and (C) total protein content was determined. Fold data were log2 transformed
to achieve normal distribution. Statistical significance was determined using the ANOVA test followed
by Dunnett’s post-hoc test. *, **, and *** indicate statistically significant difference between control and
treated samples at p < 0.05, p < 0.01 or p < 0.01, respectively. Abbreviations: TBARS—Thiobarbituric
acid-reactive substances, ALDH—Aldehyde dehydrogenase, SRB—Sulforhodamine B, GSH—reduced
glutathione, NAC—N-acetyl-cysteine.
Furthermore, GSH and NAC treatment protected against the IPA-induced decrease in
ALDH1-positive cancer stem cells (Figure 5B). More interestingly, a mitochondrial antioxidant,
Mito-TEMPO, protected against IPA-induced cytostasis (Figure 5C). These data suggest that
IPA-induced reactive species production has a central role in eliciting the widespread antineoplastic
effects of IPA.
3.4. I xerts Its ffects thro gh ryl- ydrocarbon eceptor ( ) and Pregnane X Receptor (PXR)
I as ultiple receptors [40], of which we investigated pregnane X receptor (PXR) and
aryl hydrocarbon receptor (AHR) in detail in o r study. We used pharmacological inhibitors of
AHR (CH223191) and PXR (ketoconazole [51,52]) to interrogate the involvement of IPA receptors.
The inhibition of AHR and PXR abrogated or quenched several IPA-in uced features, namely, the
IPA-induced reversion of EMT (Figure 6A), and the induction of NRF2 and AMPK (as arked by t e
os orylatio of acyl- o carboxylase, or ) (Fig re 6 ).
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statistically significant difference between control and IPA treated samples at p < 0.01. ## and ### 
indicate significant difference between control and CH223191 or ketoconazole-treated samples at p < 
0.01 or p < 0.001, respectively. Abbreviations: PXRi—PXR inhibitor, AHRi—AHR inhibitor, ACC—
acyl-CoA carboxylase (an AMPK target protein). 
We assessed whether the expression of AHR and PXR correlates with survival in human breast 
cancer using the kmplot.com database [64]. First, we assessed the RNAseq datasets and found that 
the quartile of the patient population with the highest expression has advantage in survival over the 
quartile with the lowest expression both in the case of PXR (Figure 7A) and AHR (Figure 7C). 
Figure 6. AHR and PXR are responsible for the IPA-elicited antineoplastic effects. 100,000 cells/well
4T1 cells were treated with IPA in the concentrations indicated for 24 h with or without the inhibitors,
as indicated. Subsequently, (A) the actin cytoskeleton was stained using phallodin-Texas Red, and
morphology was assessed using confocal microscopy. (B) On the same cells, the expression of the
indicated proteins were determined by Western blotting. Fold data were log2 transformed to achieve
normal distribution. Statistical significance was determined using an ANOVA test followed by
Dunnett’s post-hoc test, except for panel A, where a chi-square test was conducted. *** indicate
statistically signific t ifference between control and IPA treat d samples at p < 0.01. ## and ###
indicate significant diff ren e between control and CH223191 or ke conazole-treated samples at p < 0.01
or p < 0.001, respectively. Abbreviations: PXRi—PXR inhibitor, AHRi—AHR inhibitor, ACC—acyl-CoA
carboxylase (an AMPK target protein).
We assessed whether the expression of AHR and PXR correlates with survival in human breast
cancer using the kmplot.com database [64]. First, we assessed the RNAseq datasets and found that
the quartile of the patient population with the highest expression has advantage in survival over the
quartile with the lowest expression both in the case of PXR (Figure 7A) and AHR (Figure 7C).
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expression on survival is depicted with the data acquired from RNAseq experiments. On panel (D), 
the effect of AHR expression on survival is depicted with the data acquired from microarray 
experiments, and patients were stratified as a function of receptor expression. Total survival rates were 
assessed, and all samples are represented. Abbreviations: NR1I2—pregnane X receptor, Aryl 
hydrocarbon receptor (AHR), Pregnane X receptor (PXR) The database was assessed the 19th 
February 2020. 
Next, we assessed the microarray data as well, where we were able to stratify patients as a 
function of receptor expression (Figure 7B,D). The expression level of AHR did not have a clear 
impact on breast cancer survival; nevertheless, there was a trend for better survival in the high 
expression quartile, similarly to the RNAseq data (Figure 7D). Importantly, a higher expression of 
PXR provided better survival with breast cancer, particularly during the first 4–12 years after 
diagnosis and for estrogen receptor-positive cancer cases (Figure 7B, Table 5). 
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Figure 7. igher expression of pregnane X receptor and aryl hydrocarbon receptor prolongs survival in
breast cancer. The effect of expression of (A) AHR or (B) PXR on survival in breast cancer was analyzed
by kmplot.com, which is a freely accessible database. On panel (A), the effect of PXR expression on
survival is depicted with the data acquired from RNAseq experiments. On panel (B), the effect of PXR
expression on survival is depicted with the data acquired from microarray experiments, and patients
were stratified as a function of receptor expression. On panel (C), the effect of AHR expression on
survival is depicted with the data acquired from RNAseq experiments. On panel (D), the effect of
AHR expression on survival is depicted with the data acquired from microarray experiments, and
patients were stratified as a function of receptor expression. Total survival rates were assessed, and
all samples are represented. Abbreviations: NR1I2—pregnane X receptor, Aryl hydrocarbon receptor
(AHR), Pregnane X receptor (PXR) The database was assessed the 19th February 2020.
Next, we assessed the microarray data as well, where we were able to stratify patients as a function
of receptor expression (Figure 7B,D). The expression level of AHR did not have a clear impact on breast
cancer survival; nevertheless, there was a trend for better survival in the high expression quartile,
similarly to the RNAseq data (Figure 7D). Importantly, a higher expression of PXR provided better
survival with breast cancer, particularly during the first 4–12 years after diagnosis and for estrogen
receptor-positive cancer cases (Figure 7B, Table 5).
Table 5. Link between AHR or PXR expression and breast cancer patient survival. The effect of
expression of AHR or PXR on survival in breast cancer was analyzed by kmplot.com, which is a freely
accessible database. Total survival rates were assessed, and all samples are represented in different
subpopulations of breast cancer. Numbers in bold represent statistically significant results.
AHR (202820_at) HR (Hazard Ratio) p-Value (Log Rank Test)
All breast Cancers N = 3951 0.91 0.079
ER(+), N = 3082 0.87 0.037
ER(−), N = 869 0.96 0.68
PR(+), N = 589 0.72 0.068
PR(−), N = 549 .87 0.35
HER2(+), N = 252 .97 0.87
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Table 5. Cont.
AHR (202820_at) HR (Hazard Ratio) p-Value (Log Rank Test)
HER2(−), N = 800 0.71 0.012
ER(+), PR(+), HER2(+), N = 76 1.15 0.78
ER(−), PR(−), HER2(−), N = 198 0.84 0.48
ER(+), PR(+), N = 577 0.67 0.029
ER(−), PR(−), N = 298 0.84 0.39
ER(−), PR(−), HER2(−) N = 198 0.84 0.48
ER(+), Luminal A, N = 1933 0.87 0.11
ER(+), Luminal A, Grade 1, N = 267 0.65 0.17
ER(+), Luminal B, N = 1149 1.16 0.12
ER(+), Luminal B, Grade 1 N = 56 1.45 0.55
Grade 1, N = 345 0.67 0.13
Grade 2, N = 901 0.67 0.001
Grade 3, N = 903 0.97 0.78
Basal subtype, N = 618 0.95 0.67
Luminal A, N = 1933 0.87 0.11
Luminal B, N = 1149 1,16 0.12
ER(+), HER2(+), N = 156 1.33 0.36
ER(−), HER2(+), N = 96 0.67 0.21
ER(+), PR(+), Lymph(+) N = 344 0.61 0.026
ER(+), PR(+), Lymph(−) N = 228 0.86 0.64
ER(−), PR(−), Lymph(+) N = 127 0.85 0.54
ER(−), PR(−), Lymph(−) N = 167 0.68 0.21
ER(+), Luminal A, Grade 2, N = 567 0.69 0.027
ER(+), Luminal B, Grade 2 N = 253 0.76 0.21
PXR (207202_s_at) HR (Hazard Ratio) p-Value (Log Rank Test)
All breast Cancers N = 3951 0.8 0.00055
ER(+), N = 3082 0.84 0.0073
ER(−), N = 869 0.74 0.0056
PR(+), N = 589 1.02 0.91
PR(−), N = 549 0.9 0.49
HER2(+), N = 252 0.93 0.73
HER2(−), N = 800 1.01 0.93
ER(+), PR(+), HER2(+), N = 76 1.31 0.61
ER(−), PR(−), HER2(−), N = 198 1.08 0.75
ER(+), PR(+), N = 577 0.97 0.89
ER(−), PR(−), N = 298 0.93 0.73
ER(−), PR(−), HER2(−) N = 198 1.048 0.75
ER(+), Luminal A, N = 1933 0.77 0.0031
ER(+), Luminal A, Grade 1, N = 267 1.04 0.9
ER(+), Luminal B, N = 1149 0.81 0.031
ER(+), Luminal B, Grade1 N = 56 0.77 0.66
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Table 5. Cont.
AHR (202820_at) HR (Hazard Ratio) p-Value (Log Rank Test)
Grade 1, N = 345 0.97 0.92
Grade 2, N = 901 1.07 0.56
Grade 3, N = 903 0.98 0.83
Basal subtype, N = 618 0.78 0.053
Luminal A, N = 1933 0.77 0.0031
Luminal B, N = 1149 0.81 0.031
ER(+), HER2(+), N = 156 1.41 0.28
ER(−), HER2(+), N = 96 0.63 0.15
ER(+), PR(+), Lymph(+) N = 344 0.96 0.85
ER(+), PR(+), Lymph(−) N = 228 0.84 0.6
ER(−), PR(−), Lymph(+) N = 127 0.95 0.86
ER(−), PR(−), Lymph(−) N = 167 1.02 0.95
ER(+), Luminal A, Grade 2, N = 567 1.06 0.73
ER(+), Luminal B, Grade2 N = 253 1.23 0.34
These in silico data were complemented by characterizing the intratumoral expression of AHR
and PXR (Figure 8A) in a tissue microarray (TMA) consisting of 88 patients (the TMA was published
in [30], Cohort 2).
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When AHR expression was considered in the whole cell, it did not show any consequent change 
(data not shown); nevertheless, when we scored only the nuclear fraction of AHR that represents the 
active AHR [74], we found that the AHR nuclear score (i.e., AHR activity) decreased with the 
progression of the disease (Figure 8B). Furthermore, AHR activity was lower in highly proliferating 
tumors (Figure 8C), in tumors with lower differentiation (Figure 8D), and in not otherwise specified 
(NOS) tumors as compared to lobular tumors (Figure 8E). PXR expression decreased as the 
Nottingham grade of the patients increased (Figure 8F) and in tumors with a high proliferation rate 
(Figure 8G,H). 
3.5. Microbial Indole Biosynthesis by the Gut Microbiome Is Repressed in Early Stages of Breast Cancer 
Figure 8. Higher intratumoral expression of pregnane X receptor (PXR) and nuclear aryl hydrocarbon
receptor (AHR) shows correlation with low-grade a d lower-mitosis breast cancers. (A) TMA was
stained with the indicated antibodies. A typical staining pattern is shown. The bar is equivalent of 50
µm. Cases in TMA were scored for receptor expression using the H-score system. (B–E) H-score of the
nuclear expression of the AHR receptor were related to (B) stage of the disease, (C) mitosis score, (D)
tubule formation, and (E) histological subtype. (F–H) H-score of the expression of PXR receptor were
related to (F) grade of the disease, (G) mitosis score, and (H) mitotic index. Statistical significance on
panels B and F was determined using an ANOVA test followed by Dunnett’s post-hoc test, while on
panels C, D, E, G, and H, Student’s t-test was used. Stage 0 (in situ carcinoma) and stage 1 patients,
Mitosis score 2 and 3 patients, and tubule formation score 1 and 2 patients were handled together due
to the low number of cases. Abbreviations: A yl hydrocarbon receptor (AHR), Preg an X receptor
(PXR), no special type (NOS). *, ** and *** indicate statistically significant difference between control
and treated samples at p < 0.05, p < 0.01 or p < 0.001, respectively.
Cancers 2020, 12, 2411 18 of 27
When AHR expression was considered in the whole cell, it did not show any consequent change
(data not shown); nevertheless, when we scored only the nuclear fraction of AHR that represents
the active AHR [74], we found that the AHR nuclear score (i.e., AHR activity) decreased with the
progression of the disease (Figure 8B). Furthermore, AHR activity was lower in highly proliferating
tumors (Figure 8C), in tumors with lower differentiation (Figure 8D), and in not otherwise specified
(NOS) tumors as compared to lobular tumors (Figure 8E). PXR expression decreased as the Nottingham
grade of the patients increased (Figure 8F) and in tumors with a high proliferation rate (Figure 8G,H).
3.5. Microbial Indole Biosynthesis by the Gut Microbiome Is Repressed in Early Stages of Breast Cancer
To assess the link between bacterial IPA biosynthesis and breast cancer behavior, we assessed the
capability of the gut microbiota to synthesize indole derivatives. To that end, we identified bacterial
species in which tryptophanase operon was mapped using a database search and designed primers to
the regions coding for TnaA. We measured the abundance of the DNA coding for TnaA in fecal DNA
of recently diagnosed patients versus healthy controls (published in [3], Cohort 1) using qPCR.
When comparing patients against healthy individuals, the abundance of TnaA in Providencia
rettgeri and Alistipes shahii was significantly reduced in patients, and there was a similar trend in
Bacteroides xylanisolvens (Figure 9A). Next, we stratified patients as a function of the stage of their
disease. The decrease in TnaA abundance was accentuated in stage 0 (in situ carcinoma) patients not
only for P. rettgeri, A. shahii, and B. xylanisolvens, but also for a general probe on Clostridium species
(Figure 9B).
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Figure 9. The fecal expression of TnaA shows correlation ith the pathological and clinical features
of breast cancer. (A,B) The abundance of bacterial TnaA DNA was assessed in human fecal DNA
samples from cohort study. The ct values lower than 45 are shown in Providencia rettgeri. Median
values indicated by a line. On panel A, all patients and controls are compared, statistical significance
was calculated using Student’s t-test. On panel B, patients were stratified based on the stage of the
disease, and statistical comparison was made using an ANOVA test followed by Dunnett’s or Tukey’s
post-hoc tests. Fold data were log2 transformed to achieve normal distribution. * indicate a statistically
significant difference between control and treated samples at p < 0.05.
3.6. Fecal Protein Expression of E. coli TnaA Correlates with the Number of Tumor Infiltrating Lymphocytes
We wanted to enlarge the scope of our findings b assessing protei -level changes to bacterial
indol biosynthet c enzymes. The antibody commercially available was against the TnaA protein of E.
coli origin (Figure 10A).
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Figure 10. The fecal protein expression f . coli TnaA is higher in patients wit higher pr portions
of tumor-infiltrating lymphocytes. (A) E. coli total lysate was run on an SDS-PAGE gel, transferred
to nitrocellulose membrane, and probed with an anti-TnaA antibody. (B,C) Fecal samples of 36 low
tumor-infiltrating lymphocyte (TIL) patients (0–20% TIL) and 11 of high TIL patients (30%< TIL) were
assessed by Western blotting using an anti-TnaA antibody. Protein content-normalized values were
obtained. Values were tested for outliers using Grubb’s method; one value was omitted from the
low TIL group. (B) Normalized TnaA expression was plotted. (C) On values from low and high TIL
patients, liner regression was performed.
e determined the E. coli TnaA expression in the feces of breast cancer patients from Cohort 3.
We stratified the p tie ts based on the number of tumor-infiltrating lymphocytes (TIL) and found
that there was a trend of higher TnaA exp ession in patients with higher TIL (Figure 10B). In good
agreement with that finding, we found correlation between TIL and E. coli TnaA expression in breast
cancer patients by performing linear regression (Figure 10C).
4. Discussion
In this study, we found that a bacterial metabolite, indolepropionic acid (IPA), has antineoplastic
features (Figure 11).
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Figure 11. Schematic representation of IP -elicited effects to breast cancer cells.
IPA supplementation decreased the infiltr tion of the primary tumor to surrounding tissues, the
number of metastases, cellular movement, and diapedesis, while at the same time, it induced antitumor
immune response, mesenchymal-to-epithelial transition, oxidative stress, and influenced metabolism
through two IPA receptors, AHR and PXR (both are steroid and xenobiotic receptors [75–77]). Similar
to the effects of other antineoplastic metabolites, such as lithocholic acid or cadaverine, IPA did not
exert its cytostatic effects on non-transformed cells [27,28,65], exhibiting tumor cell-specific effects.
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Finally, we provided evidence that IPA exerts its antineoplastic modulation through the AHR and
particularly the PXR receptors.
Although the reports on the oncobiome in breast cancer are conflicting, the majority of the reports
show suppressed diversity [1–5,8,9,34,78–81] and as a consequence, limited biosynthetic capacity [4],
which is probably translated to a reduced availability of bacterial metabolites in the serum and in the
tumor [82]. It is of note that common changes to the microbiome among the different studies were
identified [12]. Furthermore, the breast’s own microbiome also changes in breast cancer patients, but
the contribution of that local microbiome depot to breast cancer is unknown [83–88].
A diverse eubiome is required for normal antitumor immunity [38,89,90]. In addition to that,
bacterial metabolites, among them, tryptophan and its metabolites [46], are capable of modulating
immunity [27,77]. Tryptophan and its downstream metabolites, including indoles, exert their effects
through the AHR and PXR receptors [91–93]. A dietary restriction of tryptophan that subsequently
limits indole production has immunosuppressive effects in an AHR-dependent fashion [94], which
correlates well with the antitumor immune response we observed in our study. High TnaA expression is
indicative of higher IPA production, and it is directly proportional with the number of tumor-infiltrating
lymphocytes. It is also important to note that tryptophan (metabolite)-dependent modulation of the
immune system can shape the composition of the microbiome [95]. IPA treatment increased oxidative
and nitrosative stress through the inhibition of the expression of NRF2 and a subsequent reduction in
cellular antioxidant defense (e.g., downregulation of caspase expression).
In addition, IPA induced iNOS expression and enhanced mitochondrial reactive species production.
NRF2 downregulation and iNOS overexpression was shown for lithocholic acid and indoxylsulfate,
which are other cytostatic bacterial metabolites, although neither of these metabolites induced
mitochondrial reactive species production [30,96]. NRF2 and iNOS have profound roles in setting the
redox balance in cancer cells [67,97]. Increased oxidative and nitrosative stress is cytostatic in breast
cancer [30,66,69,70]. An increase in reactive species production is vital to exert the cytostatic properties
of IPA. Furthermore, oxidative stress is a key regulator of cancer cell stem-ness [98], and higher levels
of oxidants switch cancer stem cells to lose their stem properties [99–101]. IPA treatment reduced the
proportions of cancer stem cells, which is an effect that was reverted by the addition of thiol reductants.
The oncobiome has a pivotal role in regulating EMT and metastasis formation [27–29,31,32,96].
IPA induced mesenchymal-to-epithelial transition (MET), as found with other microbial
metabolites [27,28,96,102]. Inducing MET slows down cell movement, diapedesis, and metastasis
formation. In our models, we observed that IPA supplementation reduced metastasis formation.
In addition to these findings, we showed that IPA induces AMPK, FOXO1, and PGC1β, which
are enzymes inducing mitochondrial biogenesis, in an AHR/PXR-dependent fashion. The activation
and overexpression of these enzymes were shown to be associated with better survival in breast
cancer [27,53,103,104].
Are these observations relevant to human breast cancer? Tryptophan and indole metabolism is
tightly associated with breast cancer and breast cancer survival. High extracellular tryptophan levels
associate with worse survival in breast cancer (Table S8 [105]). The levels of an indole derivative,
3-indoxyl-sulfate—a downstream metabolite of tryptophan degradation and indole propionic acid
formation—is downregulated both in estrogen receptor-positive and negative cases ([106] Additional
file 3, Table S3 Line 44). Furthermore, in breast tumors, there is a negative correlation between Ki67
positivity (a proliferation marker) and 3-indoxyl-sulfate levels ([106] Additional file 9, Table S8 line
130). These data suggest that indole derivatives support the survival of patients with breast cancer and
that their levels are downregulated with progressive disease. In addition to these, we showed that
the IPA biosynthetic capacity of the microbiome is reduced in women newly diagnosed with breast
cancer, especially for women with in situ carcinoma, mirroring associations with other gut microbial
metabolites, lithocholic acid [27] and cadaverine [28]. These observations are also in good correlation
with the intratumoral expression pattern and activity of AHR and PXR that are downregulated with
the progression of the disease, or were lower in aggressive, highly proliferative, and undifferentiated
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breast cancer cases. The model that we can build from the data we represented and from the available
literature is that in breast cancer, oncobiosis bacterial tryptophan metabolism is suppressed, and this
seems to be the most profound in early stage, in situ carcinoma cases. Decreases in IPA release the
cytostatic lockdown of breast cancer cells. Later stage and aggressive cases are characterized by a
lower expression or lower activity of metabolite-elicited signaling. Apparently, oncobiosis seems to
play a role in breast carcinoma progression but not in the initiation of the disease.
As we noted above, accumulating evidence suggests a functional role of the oncobiome in breast
cancer, as seen in human population-based studies and animal studies on antibiotic use, metabolite
supplementation studies, nutritional studies [107], and pharmacological studies [108] such as the one
we are presenting hereby. These studies open new approaches in breast cancer treatment through
identifying bacterial metabolites and elements of the oncobiome that can be exploited in therapy.
5. Conclusions
In this paper we showed that IPA has cytostatic and antineoplastic properties in breast cancer.
IPA reduced the proportions of cancer stem cells and the proliferation, movement, and metastasis
formation of cancer cells. These were achieved through inhibiting epithelial-to-mesenchymal transition,
inducing oxidative and nitrosative stress, and boosting antitumor immune response. IPA exerted its
effects through aryl hydrocarbon receptor (AHR) and pregnane X receptor (PXR) receptors. A higher
expression of PXR and AHR supported better survival in human breast cancer patients, highlighting
the importance of IPA-elicited pathways in cytostasis in breast cancer. Furthermore, AHR activation
and PXR expression related inversely to cancer cell proliferation level and to the stage and grade of
the tumor. The fecal microbiome’s capacity for IPA biosynthesis was suppressed in women newly
diagnosed with breast cancer, especially with stage 0. Bacterial indole biosynthesis showed correlation
with lymphocyte infiltration to tumors in humans. Bacterial metabolites (e.g., lithocholic acid, short
chain fatty acids or cadaverine), among them, IPA, have a pivotal role in regulating the progression
but not the initiation of the disease.
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